Document Detail

L-threonine in the treatment of spasticity.
MedLine Citation:
PMID:  1742749     Owner:  NLM     Status:  MEDLINE    
Preclinical data indicate that the administration of the amino acid L-threonine increases glycine levels in rat spinal cord. In order to investigate glycinergic mechanisms in spasticity, and other signs of the upper motor syndrome, we gave 4.5 and 6.0 g/day of L-threonine to 18 patients with familial spastic paraparesis (FSP) according to a double-blind, crossover protocol. The response to treatment at the end of each 2-week period was based upon three measures: the physician's global impressions; the patients' global impressions; and semiquantitative ratings of strength, muscle tone, DTRs, walking, hopping, and running. Blood and CSF were collected during each treatment period for amino acid analyses. Based upon the severity rating scales, there was a statistically significant (p less than 0.02) decrease in motor impairment and spasticity during L-threonine administration compared to placebo treatment; significant treatment effects were not found on the physician's and patients' global impressions. Plasma and CSF levels of threonine increased significantly during L-threonine treatment but glycine levels did not change. These data indicate that L-threonine significantly suppressed the signs of spasticity even though the benefits were not clinically valuable.
J H Growdon; T M Nader; J Schoenfeld; R J Wurtman
Related Documents :
24432119 - Radiographic parameters improve lower extremity prosthetic alignment.
9552059 - Demyelination and single-carbon transfer pathway metabolites during the treatment of ac...
22923269 - Laser and led phototherapies on angiogenesis.
23610989 - Outcomes of reoperative aortic valve replacement via right mini-thoracotomy versus medi...
9544169 - Pregnancy during therapy for childhood acute lymphoblastic leukemia: two case reports a...
7199359 - Recurrence of thrombocytopenia in patients splenectomized for idiopathic thrombocytopen...
11318279 - Cystoid macular oedema in uveitis: an unsolved problem.
25123399 - Triphenylamine groups improve blocking behavior of phenoxazine dyes in cobalt-electroly...
16443059 - The 800-nm diode laser in the treatment of leg veins: assessment at 6 months.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  14     ISSN:  0362-5664     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-01-10     Completed Date:  1992-01-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  403-12     Citation Subset:  IM    
Department of Neurology, Massachusetts General Hospital, Boston 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Double-Blind Method
Middle Aged
Spastic Paraplegia, Hereditary / drug therapy*
Threonine / administration & dosage,  blood,  therapeutic use*
Grant Support
5-M01-RR-01066/RR/NCRR NIH HHS
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Banisterine and Parkinson's disease.
Next Document:  Interactions of sleep and clonidine on daytime prolactin secretion in humans.